Both in Biotechnology
Outlook Therapeutics vs Neumora Therapeutics
Over the past year OTLK returned −64.6% and NMRA returned −81.0%; their daily moves had a correlation of 0.17.
OTLK −64.6% NMRA −81.0%Growth of $1, one year, split-adjusted
| Metric | OTLK | NMRA |
|---|---|---|
| Price | $0.4600 | $0.5709 |
| Market cap | $112.0M | $107.3M |
| Today | −1.96% | +15.17% |
| 1 month | −22.8% | +8.7% |
| 6 months | +90.3% | −75.2% |
| Year to date | −70.9% | −68.1% |
| 1 year | −63.5% | −81.1% |
| Revenue growth (YoY) | −99.4% | — |
| Gross margin | −95.0% | — |
| Net margin | −233554.9% | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | -$7.0M | $63.9M |
| Dividend yield | — | — |
| Volatility (60d) | 89.0% | 126.3% |
| Short % of float | 39.3% | 6.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).